source
- Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trialAt the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…
- Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trialA Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…